Found 8 matching trials
A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis
PHASE1The study will be conducted in two parts. The first (Part A) will be an ope...
Location
GSK Investigational Site
Phase 1 Study of GSK2315698 in Healthy Japanese Subjects
PHASE1This is the first study in which GSK2315698 will be administered in Japanes...
Location
GSK Investigational Site
Depletion of Serum Amyloid P Component to Enhance the Immune Response to DNA Vaccination
PHASE1This is a clinical proof-of-concept (PoC) study of DNA vaccination after SA...
Location
National Amyloidosis Centre
A Safety Study of GSK3039294 in Healthy Volunteers and Patients With Systemic Amyloidosis
PHASE1GSK3039294 has been developed in order to offer an orally available alterna...
Location
GSK Investigational Site
SAP Depleter Dose Assessment Study in Patients
PHASE1This study aims to provide safety information on the ligand, GSK2315698A. T...
Location
GSK Investigational Site
Multiple Treatment Session Study to Assess GSK2398852 Administered Following and Along With GSK2315698
PHASE2The study is intended to evaluate whether monthly repeated courses of admin...
Location
GSK Investigational Site
Biodistribution of 89Zirconium-labelled GSK2398852 Using PET Imaging
PHASE1The principal aim of this study is to investigate the cardiac uptake of 89Z...
Location
GSK Investigational Site
SAP Depleter Dose Escalation Study in Healthy Volunteers
PHASE1The purpose of this study is to provide safety information and to define th...
Location
GSK Investigational Site